


SUPPLEMENTARY MATERIAL
FIGURE



Supplementary Figure. Evaluation of clinical parameters in patients with complete data at the 3 follow-up visits. Changes in ACT (A), AQLQ (B), FeNO (C) and lung function (D) at baseline, and at 4 and 12 weeks after administration of dupilumab. ACT indicates Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; FeNO, fractional inhaled nitric oxide.
^aFriedman signed rank test. Each panel shows the median (IQR).